Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
GENETIC FACTORS FOR OSTEOPOROSIS (GEFOS)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Netherlands,Greece,United Kingdom,Iceland,United Kingdom,United Kingdom,Sweden,United Kingdom,Australia,United States
Call:  (FP7-HEALTH-2007-A, 2007)
Start date: 2008-03-01
End date: 2012-08-31
Duration (months): 54.0
Total project cost (EUR): 4648972.0
EU funding (EUR): 2998650.0
Participants: 11
Project status: CLOSED

Osteoporosis is a common, age-related disease with a strong genetic component. With increasing age of the population, Europe and industrialised countries across the globe are facing a substantial increase in osteoporotic fractures, which account for considerable disease-burden and costs. Early identification and treatment of subjects at risk can help preventing this, and genetic susceptibility alleles are the most promising risk factors in this respect. Large-scale prospective meta-analysis of individual gene polymorphisms in the EU-funded GENOMOS consortium was shown successful in identifying the expected subtle effects of gene polymorphisms which predispose to osteoporosis. The recent development of powerful genome-wide genotyping technology now allows to identify -hypothesis free- strong and common genetic risk factors for complex diseases by Genome Wide Association (GWA) analysis. The AIM of the proposal is to identify osteoporosis susceptibility alleles by meta-analysis of GWA data obtained from a large collection of osteoporosis genetics cohorts in Europe and outside (n=46.000). Prospective meta-analysis of GENOMOS, a large consortium of genetic studies on osteoporosis (n=80.000), is used to assess generalizability of genetic effects and develop sufficient power to quantify even small, but clinically important risks. The improvement in clinical risk-assessment for osteoporosis by adding the diagnostic panel of osteoporosis risk-alleles identified in this project, will be quantified in prospective studies including genetic and classical risk factors.

Keywords: osteoporosis-genetics-statistics-populations-risk models
DIsseminate Research funded by EC improving Treatment options for children suffering from cancer (DIRECT)

Framework: FP7 — Cooperation
Programme: Health
Destination: Other Actions across the Health Theme
Action type: Coordination and support actions
Countries involved: Austria,Germany
Call:  (FP7-HEALTH-2007-A, 2007)
Start date: 2008-03-01
End date: 2010-10-31
Duration (months): 32.0
Total project cost (EUR): 708160.0
EU funding (EUR): 618000.0
Participants: 4
Project status: CLOSED

Science is an endeavour that relies on a society committed to allocate substantial resources to its pursuit. Clear communication of research projects and their results is an essential part of performing science with public funds. However, progress in science is often slow, achievements of relevance to the society occur mostly in many iterative steps and the benefit for the public can hardly ever be associated with a single breakthrough discovery. While publicly funded research is increasingly openly accessible, complex individual findings require a more global approach to make their societal benefits tangible. “Children suffering from cancer” is a highly emotional issue which catches the attention of those not directly concerned. Moreover, research from public funds, including the Framework Programmes has contributed to the substantial advances in paediatric oncology, which provided instrumental results for improved treatment options and an increasing rate of young patients overcoming their malignant disease. To raise the interest in and understanding of health research, DIRECT aims at making the most of the general concern for the well-being of children. The partners of this consortium are convinced that this project will be able to increase the acceptance of and understanding for EC funded health research in the general public through the proposed strategy. Our approach is based on carefully selected projects in paediatric oncology and a mountaineering event to highlight the good physical condition of former patients in a transparent and instructive way for the public. Thus we will aim at providing an obvious link between EC funded research activities and the health of youths having overcome malignant disease. This link will be documented with the help of media professionals and communicated to the general public using ‘state of the art’ dissemination tools, including the internet, audio/visual and print media.

Keywords: paediatric oncology,documentary,science communication,event,public awareness,human factor
Brains in Dialogue: Brain Science at the service of European citizens (BID)

Framework: FP7 — Cooperation
Programme: Health
Destination: Other Actions across the Health Theme
Action type: Coordination and support actions
Countries involved: Italy
Call:  (FP7-HEALTH-2007-A, 2007)
Start date: 2008-03-01
End date: 2011-08-31
Duration (months): 42.0
Total project cost (EUR): 555523.6
EU funding (EUR): 497075.0
Participants: 1
Project status: CLOSED

Main goal of the project is to build an effective dialogue among key-stakeholders in a crucial area of health advancement: Brain Science, and in particular Predictive Medicine, Brain Imaging and Brain Machine Interfaces. Advancements in these fields continuously provide new and very valuable information aimed at understanding how the most vital organ works and how neurological diseases can be treated. Our project will establish a fruitful dialogue and public engagement among European stakeholders in these areas by: · Organising a series of workshops and open forums to produce accurate and sound scientific information on the state of the art, the promises and the risks linked to those topics and discuss the associated ethical and social issues. · Building a press office able to spread the collected information efficiently. · Establishing and maintaining a website hosting a radio and TV-web activity to disseminate the information at different levels and facilitate the communication. We will involve all social actors interested in the advancement of medicine raising a concrete discussion among scientists, clinicians, pharmaceutical companies, health operators (managers, technicians and attendants of health structures, etc...), patients’ associations, experts in ethics, legal and social issues dealing with those topics. In particular, involving health operators, who are the real brokers between the medical science and patients, and delegates of targeted patients’ associations, is a crucial point if we want to foster a wide dialogue between the scientific community and the public, while taking into account the specificity of the different European countries. Therefore, the project has a double mission: a scientific one, to be realised through the workshops activity and a collection of data from the existing EU-funded Brain Science projects; and a communicative one, to be realised through the creation of a Press Office linked with the major European media officers and a website. This scientific and communicative commitment will be of great help to the European Community to improve the understanding of the new discoveries and therapies available for Brain Diseases and will be determinant for the welfare and health of European citizens.

Keywords: predictive medicine in brain science,brain imaging,brain machine interface,dialogue,stakeholders
IBD: proteases offer new targets for drug discovery (IPODD)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: United Kingdom,United Kingdom,United Kingdom,Italy,Germany,Czechia,Netherlands,Ireland,Ireland,New Zealand,Germany
Call:  (FP7-HEALTH-2007-A, 2007)
Start date: 2008-06-01
End date: 2011-05-31
Duration (months): 36.0
Total project cost (EUR): 3878507.2
EU funding (EUR): 2999250.0
Participants: 12
Project status: CLOSED

The inflammatory bowel diseases (IBD) which comprise Crohn’s disease and ulcerative colitis are chronic relapsing and remitting inflammatory disorders of the gastrointestinal tract. The frequency of these conditions has increased in recent decades, particularly in countries making the transition from developing to developed nation status. In western Europe, IBD now affects between 1/1000 and 5/1000 of the population, and the prevalence of the conditions in new EU accession countries appears to be growing as they develop. Few conditions in all of clinical medicine are linked with as much morbidity and potential mortality as IBD. Current treatment is based upon steroid therapy or neutralizing the effect of pro-inflammatory cytokines, especially TNFalpha. Despite their efficacy, many patients eventually require surgery for refractory disease or complications (stricture, perforation, abscess). In response to the call we have assembled a multidisciplinary team of international experts to delineate the role of intestinal proteases and their inhibitors in the pathophysiology of IBD. A particularly innovative aspect of our approach is the examination of both bacterial and host derived proteases and interactions between the two. The ultimate aim is develop novel therapeutics and increased understanding of the disease both of which will impact within the wider EU community and globally.

Keywords: proteases,protease activated receptors,polymorphisms,microflora,colon,mucosa,neuro-immune function
Combating influenza using a novel drug strategy (FLUDRUGSTRATEGY)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Sweden,Germany,Bulgaria,Netherlands,Sweden
Call:  (FP7-HEALTH-2007-A, 2007)
Start date: 2008-03-01
End date: 2010-08-31
Duration (months): 30.0
Total project cost (EUR): 1940609.0
EU funding (EUR): 1498396.0
Participants: 5
Project status: CLOSED

Objective: To find and produce novel target compounds against the influenza virus. Influenza A capsid protein is the target since it does not mutate at the same rate as the Hemagglutinin or Neuraminidase proteins. We aim to develop new therapeutic antiviral solutions to combat the disease. Beyond state of the art: The project combines knowledge based design and synthesis of compounds with unique patented image analysis and mathematical algorithm software to find and develop new types of potential antiviral molecules. The expertise and methodology allows for rapid discovery of lead molecules with the potential to provide new classes of drugs/vaccines which are less sensitive to viral mutation or reassortment. Work plan: Key molecules with optimal binding kinetics to the Influenza capsid protein will be designed and synthesized then analysed and tested in two separate experimental systems for their effect upon the virus structure and maturation process. The evaluation of novel lead drugs will be performed using a combination of new rapid image analysis, backed up by established viral analysis techniques. Finally a plan will be created for the continued verification and development of the lead molecules. Impact: We aim to produce a new class of antiviral drug candidates which specifically bind to influenza A capsid protein. These substances may have two potential effects; 1. Binding could inhibit important protein-protein interactions thereby inhibit virus formation. 2. Binding to the capsid protein could change the virus structure or stabilize the virus particle, resulting in non-infectious particles to which the host´s immune system could respond. The expected impact will be i) identification of targets against influenza to provide new therapeutic options ii) new opportunities to develop an anti-influenza vaccine which might help prevent an influenza pandemic, iii) to support the continued commercial development of the two SME partners.

Keywords: capsid,electron microscopy,image analysis,drug target,organic compound,protein-protein interaction
Profiling the toxicity of new drugs: a non animal-based approach integrating toxicodynamics and biokinetics (PREDICT-IV)

Framework: FP7 — Cooperation
Programme: Health
Destination: Biotechnology, generic tools and medical technologies for human health
Action type: Collaborative project
Countries involved: Germany,Germany,Austria,Italy,France,European organisations area,Switzerland,France,France,Ireland,Netherlands,United Kingdom,Germany,France,Germany,Germany,Austria,Austria
Call:  (FP7-HEALTH-2007-A, 2007)
Start date: 2008-05-01
End date: 2013-10-31
Duration (months): 66.0
Total project cost (EUR): 16426328.2
EU funding (EUR): 11330906.0
Participants: 20
Project status: CLOSED

The overall aim of Predict-IV is to develop strategies to improve the assessment of drug safety in the early stage of development and late discovery phase, by an intelligent combination of non animal-based test systems, cell biology, mechanistic toxicology and in-silico modelling, in a rapid and cost effective manner. A better prediction of the safety of an investigational compound in early development will be delivered. Margins-of-safety will be deduced and the data generated by the proposed approach may also identify early biomarkers of human toxicity for pharmaceuticals. The results obtained in Predict-IV will enable pharmaceutical companies to create a tailored testing strategy for early drug safety. The project will integrate new developments to improve and optimize cell culture models for toxicity testing and to characterize the dynamics and kinetics of cellular responses to toxic effects in vitro. The target organs most frequently affected by drug toxicity will be taken into account, namely liver and kidney. Moreover, predictive models for neurotoxicty are scarce and will be developed. For each target organ the most appropriate cell model will be used. The approach will be evaluated using a panel of drugs with well described toxicities and kinetics in animals and partly also in humans. This approach will be highly advantageous as it will allow a direct comparison between the in vivo to the in vitro data. A parallel analysis of several dynamic and kinetic models with a broad spectrum of endpoints should allow for the identification of several relevant biomarkers of toxicity. Inter-individual susceptibilities will be taken into account by integrating the polymorphisms of the major drug metabolizing enzymes and correlating the observed effects in the human cell models with their genotype. Environmental influences on cellular toxicity to these compounds will also be evaluated using hypoxic stress as a relevant test model.

Keywords: pharmaceuticals,toxicity testing,alternative methods
Genomic instability and genomic alterations in pre-cancerous lesions and/or cancer (GENINCA)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Austria,Italy,United Kingdom,Germany,Germany,France,Germany,Austria,Germany,United Kingdom,Germany
Call:  (FP7-HEALTH-2007-A, 2007)
Start date: 2008-01-01
End date: 2011-06-30
Duration (months): 42.0
Total project cost (EUR): 4033238.15
EU funding (EUR): 2995569.0
Participants: 14
Project status: CLOSED

GENINCA will address two tumor entities, for which we have good access to pre-malignant lesions and in which genomic instability is a common feature: colorectal and liver cancer. Colorectal cancer amounts to 13.2% of all incident cases of cancer, the second most common form of cancer, surpassed only by lung cancer (13.3%). Liver cancer accounts for about 2% of total cancers, however, the most common liver cancer, i.e. hepatocellular carcinoma (HCC), is among the most lethal form of cancer, and its incidence in Europe has been steadily rising over the last few decades. GENINCA represents a collaborative study of 8 academic and 3 industrial partners from 5 European countries. GENINCA will focus on exploring pre-cancerous and cancer lesions of the two aforementioned tumor entities and their respective microenvironment. As the recent identification of human colon-cancer initiating cells by one of our academic consortium members paves the way for completely new strategies for studying mechanisms of tumorigenesis, a particular focus of this grant proposal will be the detailed characterization of these cancer initiating stem cells. At present, it is still a matter of debate which genomic changes are already present in precursor lesions and whether these lesions already show genetic instability. We will therefore address the occurrence of genomic instability and explore their underlying mechanisms especially in pre-cancerous and early cancer lesions. This will be greatly facilitated by in vivo endomicroscopy approaches, sophisticated animal models and large-scale genomic and proteomic analyses. Furthermore, we will include an in-depth analysis of the corresponding microenvironment. As this represents a translational research effort, we expect to identify markers for novel therapeutic and/or preventative strategies, as well as to facilitate tumor diagnosis, prognosis, and monitoring.

Keywords: genomic instabilities,cancer,proteomic analyses,early cancer lesions,tumor diagnosis,tumor prognosis,tumor monitoring,endomicroscpy approaches
Lipid droplets as dynamic organelles of fat deposition and release: Translational research towards human disease (LIPIDOMICNET)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Germany,Netherlands,Italy,France,Netherlands,Switzerland,Austria,Sweden,Germany,Hungary,United Kingdom,Finland,Germany,Germany,Germany,Germany,Germany,United Kingdom,United Kingdom,Austria,Russian Federation,Germany,Poland,Austria,Slovakia,Spain
Call:  (FP7-HEALTH-2007-A, 2007)
Start date: 2008-05-01
End date: 2012-10-31
Duration (months): 54.0
Total project cost (EUR): 16022988.28
EU funding (EUR): 11603930.0
Participants: 27
Project status: CLOSED

Lipids are central to the regulation and control of cellular processes by acting as basic building units for biomembranes, the platforms for the vast majority of cellular functions. Recent developments in lipid mass spectrometry have set the scene for a completely new way to understand the composition of membranes, cells and tissues in space and time by allowing the precise identification and quantification of alterations of the total lipid profile after specific perturbations. In combination with advanced proteome and transcriptome analysis tools and novel imaging techniques using RNA interference, it is now possible to unravel the complex network between lipids, genes and proteins in an integrated lipidomics approach. This project application of the European Lipidomics Initiative (ELife; www.lipidomics.net) will address lipid droplets (LD) as dynamic organelles with regard to composition, metabolism and regulation. LD are the hallmark of energy overload diseases with a major health care impact in Europe. The project will exploit recent advances in lipidomics to establish high-throughput methods to define drugable targets and novel biomarkers related to LD lipid and protein species, their interaction and regulation during assembly, disassembly and storage. Translational research from mouse to man applied to LD pathology is a cornerstone of this project at the interface between research and development. To maximize the value of the assembled data generated throughout the project, “LipidomicNet” as a detailed special purpose Wiki formate data base will be developed and integrated into the existing Lipidomics Expertise Platform (LEP) established through the SSA ELife project (www.lipidomics-expertise.de). ELife collaborates with the NIH initiative LIPID MAPS (www.lipidmaps.org) and the Japanese pendant Lipidbank (www.lipidbank.jp) and is connected to the Danubian Biobank consortium (SSA DanuBiobank, www.danubianbiobank.de) for clinical lipidomics.

Keywords: lipid droplet research from mouse to man,lipid protein interaction,high-throughput,lipidomicnet
The role of peptidoglycan in bacterial cell physiology: from bacterial shape to host-microbe interactions (PGNFROMSHAPETOVIR)

Framework: FP7 — Ideas
Programme: European Research Council
Theme: European research council
Destination: Starting grants
Action type: Support for frontier research (ERC)
Panel: Cellular and Developmental Biology
Countries involved: France
Call:  (ERC-2007-StG, 2007)
Start date: 2008-08-01
End date: 2013-07-31
Duration (months): 60.0
Total project cost (EUR): 1650000.0
EU funding (EUR): 1650000.0
Participants: 1
Project status: CLOSED

Peptidoglycan (PGN) is a major essential and unique component of the cell wall of both of Gram-negative and Gram-positive bacteria. Because of the central role of PGN metabolism in bacterial cell structure and shape, in antibiotic resistance and in host-microbe interactions, any process affecting one of these aspects has direct consequence on the other two. Hence, the study of PGN metabolism is of seminal importance for a better understanding of bacteria in their environment. My project is centered on these three major aspects of PGN metabolism using several bacterial models. The project can be divided in two parts, one aimed at studying PGN metabolism to better understand how bacteria assemble a mature PGN that confers rigidity and shape to the cell despite a highly dynamic process to accompany cell growth and division (Part A). I propose to continue using Helicobacter pylori as a bacterial model since genome analysis indicates a minimal set of genes involved in PGN metabolism and assembly suggesting it might be a simpler model to study PGN metabolism. By characterizing the role of H. pylori PGN synthetases and hydrolases, my aim is to better understand PGN metabolism and to develop new therapeutic/antimicrobial strategies. The second part of my research project (Part B) is aimed at studying the role of PGN in host-microbe interactions and its detection by the recently identified intracellular receptors Nod1 and Nod2. Using several bacterial models, the objective is to understand how pathogens are able to subvert/modulate the host response by modifying their PGN. The different models include Helicobacter pylori, Neisseria meningitidis, Yersinia sp., Listeria monocytogenes among others. A second objective is to understand the dynamics of PGN sensing in the host cell during infection: which PGN structures are presented by the different pathogens, how the host detects them, responds to them and eventually detoxifies them.

Keywords: peptidoglycan,penicillin-binding protein,autolysin,lysozyme,bacterial shape,infectious disease,nod1,nod2,tlr,innate immunity,inflammation